Daou B, Chalouhi N, Starke RM, et al. Clipping of previously coiled cerebral aneurysms: efficacy, safety, and predictors in a cohort of 111 patients. J Neurosurg. 2016;125(December):1-7. doi:10.3171/2015.10.JNS151544.
This retrospective cohort study evaluated the efficacy and safety of microsurgical clipping in the treatment of recurrent, previously coiled cerebral aneurysms and to identify risk factors that can affect the outcomes of this procedure. The mean patient age was 50.5 years, the mean aneurysm size was 7 mm, and 97.3% of aneurysms were in the anterior circulation. Complete aneurysm occlusion, as assessed by intraoperative angiography, was achieved in 97.3% of aneurysms (108 of 111 patients). Among patients, 1.8% had a recurrence after clipping. Retreatment was required in 4.5% of patients after clipping. Major complications were observed in 8% of patients and mortality in 2.7%. Ninety percent of patients had a good clinical outcome. Aneurysm size and location in the posterior circulation were significantly associated with higher complications. All 3 patients who had coil extraction experienced a postoperative stroke.
They conclude that surgical clipping is an appropriate treatment strategy for the management of recurrent cerebral aneurysms after endovascular coiling. Direct clipping of the aneurysm neck is feasible in most cases of recurrent, previously coiled cerebral aneurysms. Coil extraction should not regularly be attempted because it is associated with high morbidity. In other words, when direct clipping is not possible because of coil loops extending into the aneurysm neck, or with transmural calcification and scarring, other techniques such as wrapping should be considered.
Serrone JC, Tackla RD, Gozal YM, et al. Aneurysm growth and de novo aneurysms during aneurysm surveillance. J Neurosurg. 2016;125(6):1374-1382. doi:10.3171/2015.12.JNS151552.
Over an 11.5-year period, the authors recommended surveillance imaging to 192 patients with 234 unruptured intracranial aneurysms. The incidence of unruptured intracranial aneurysm growth and de novo aneurysm …
Domino JS, Baek J, Meurer WJ, et al. Emerging temporal trends in tissue plasminogen activator use. Neurology. 2016;87(21):2184-2191. doi:10.1212/WNL.0000000000003349.
Mexican Americans (MA) have an increased stroke burden when compared to their non-Hispanic white (NHW) counterparts, including increased stroke incidence and poorer neurologic, functional, and cognitive outcomes.
The authors explored the temporal trends in tissue plasminogen activator (tPA) administration for acute ischemic stroke (AIS) in a biethnic community without an academic medical center. Cases of AIS were identified from 7 hospitals in the Brain Attack Surveillance in Corpus Christi (BASIC) project, a population-based surveillance study from 2000-2012. There were 5,277 AIS cases identified from 4,589 individuals. tPA use was steady at 2% and began increasing in 2006, reaching 11% in subsequent years. Although ethnicity did not modify the temporal trend, Mexican Americans were less likely to receive tPA than non- Hispanic whites due to emerging ethnic differences in later years. The results suggest that increases in tPA use were greater in higher severity patients compared to lower severity patients, and a gap between MAs and NHWs in tPA administration may be emerging. The authors conclude that as physician experience with tPA and its use in community settings increases, follow-up studies should continue to explore temporal trends in tPA as well as identify possible strategies to improve tPA use in MAs.
2 Figures (graphs), 2 Tables
Goldstein LB. IV tPA for acute ischemic stroke. Neurology. 2016;87(21):2178-2179. doi:10.1212/WNL.0000000000003366.
In this editorial on the Domino et al. paper, Dr. Goldstein notes that there were considerable barriers that slowed IV tPA adoption after it was approved by the FDA in 1996. Eight years after FDA approval, IV tPA was being given to only 1%–2% of stroke patients. Transformation of the structure and organization of stroke care delivery were needed, and in part led to …
The Editors of AJNR are pleased to announce the annual Lucien Levy Best Research Article Award has been presented to:
Brain Network Architecture and Global Intelligence in Children with Focal Epilepsy by M.J. Paldino, F. Golriz, M.L. Chapieski, W. Zhang, and Z.D. Chu.
This award is named for the late AJNR Senior Editor who championed its establishment and recognizes the best original research paper accepted in 2016. The winning paper, submitted by authors from the Texas Children’s Hospital in Houston, was published electronically on October 13, 2016 and appeared in the February print issue. It was selected by a vote of the Journal’s Editor-in-Chief and Senior Editors.
Other nominated papers were:
Fate of Coiled Aneurysms with Minor Recanalization at 6 Months: Rate of Progression to Further Recanalization and Related Risk Factors by , and
Porcine In Vivo Validation of a Virtual Contrast Model: The Influence of Contrast Agent Properties and Vessel Flow Rates by , and
MR Imaging of Individual Perfusion Reorganization Using Superselective Pseudocontinuous Arterial Spin-Labeling in Patients with Complex Extracranial Steno-Occlusive Disease by , and
A Semiautomatic Method for Multiple Sclerosis Lesion Segmentation on Dual-Echo MR Imaging: Application in a Multicenter Context by …
Akoudad S, Wolters FJ, Viswanathan A, et al. Association of Cerebral Microbleeds With Cognitive Decline and Dementia. JAMA Neurol. 2016;73(8):934. doi:10.1001/jamaneurol.2016.1017.
The authors wanted to determine whether microbleed count and location were associated with an increased risk for cognitive impairment and dementia. They evaluated a prospective population-based study set in the general community, and assessed the presence, number, and location of microbleeds at baseline (August 2005 to December 2011) on brain MRI in 4841 participants 45 years or older. Trained research physicians, blinded to clinical data, reviewed the MRs. Cerebral microbleeds were defined as small, round to ovoid areas of focal signal loss on T2- weighted images. Participants underwent neuropsychological testing at 2 time points approximately 6 years apart, and were also followed up for incident dementia. 3257 participants underwent baseline and follow-up cognitive testing. Microbleed prevalence was 15.3%. The presence of more than 4 microbleeds was associated with cognitive decline. The presence of microbleeds was associated with an increased risk for dementia after adjustment for age, sex, and educational level, including Alzheimer dementia.
The strengths of this study, according to the authors, is the longitudinal population based design with a large sample size, the use of an extensive neuropsychological test battery, and the virtually complete screening for incident dementia. Limitations include multiple statistical tests, increasing the chance of type I errors. Second, selection bias may have influenced the results, because healthier people without subjective memory complaints were more likely to receive follow-up cognitive testing. Most importantly perhaps, the microbleed number may not reflect the true biological number because microbleed detection strongly depends on technical imaging methods used. T2W images were used, and as we know, SWI is far superior for the detection of these lesions.
Manoso MW, Moore TA, Agel J, Bellabarba C, Bransford RJ. Floating
Austein F, Riedel C, Kerby T, et al. Comparison of Perfusion CT Software to Predict the Final Infarct Volume After Thrombectomy. Stroke. 2016 doi:10.1161/STROKEAHA.116.013147.
The purpose of the study was to determine the accuracy of different commercial perfusion CT software packages to predict the final infarct volume (FIV) after mechanical thrombectomy. Packages evaluated included 1) Philips Brain CT Perfusion Package, Philips Healthcare, The Netherlands, 2) Siemens (Syngo Volume Perfusion CT Neuro, Siemens Healthcare, Erlangen, Germany, and 3) RAPID (iSchemaView Inc, Menlo Park, CA). CTP data from 147 mechanically recanalized acute ischemic stroke patients were postprocessed. Ischemic core and final infarct volume were compared about thrombolysis in cerebral infarction (TICI) score and time interval to reperfusion. Final infarct volume was measured at follow-up imaging between days 1 and 8 after stroke. Significant differences were found between the packages about over- and underestimation of the ischemic core, with RAPID best-predicting hypoperfusion volume in nonsuccessfully recanalized patients. They conclude that this software package overestimated the final infarct volume to a significantly lower degree and estimated a malignant mismatch profile less often than other software.
Tan BYQ, Wan-Yee K, Paliwal P, et al. Good Intracranial Collaterals Trump Poor Alberta Stroke Program Early CT Score for Intravenous Thrombolysis in Anterior Circulation Acute Ischemic Stroke. Stroke. 2016 doi:10.1161/STROKEAHA.116.013879.
As a nice background and reference to describe the various collateral scoring systems, see: Yeo et al, Assessment of Intracranial Collaterals on CT Angiography in Anterior Circulation Acute Ischemic Stroke, AJNR 2015.
The authors evaluated the prognostic effect of the collateral circulation in patients with thrombolysed acute ischemic stroke who have large early infarct sizes as indicated by low ASPECTS score. They stratified patients using ASPECTS into 2 groups: large volume infarcts (ASPECTS≤ 7 points) and small volume infarcts (ASPECTS 8–10). They also evaluated a third group …
Saber H, Silver B, Santillan A, Azarpazhooh MR, Misra V, Behrouz R. Role of emergent chest radiography in evaluation of hyperacute stroke. Neurology. 2016;87(8):782–785. doi:10.1212/WNL.0000000000002964.
Despite evidence supporting the prompt administration of IV rtPA, fewer than one-third of acute ischemic stroke patients receive this medication within the target window of 60 minutes or less. Patient and technical factors often contribute to delays in the so-called door-to-needle time or the period from hospital presentation to initiation of treatment. Given this background, the authors compared features of patients who had a CXR done before IV thrombolytics with those who did not. Rates of cardiopulmonary adverse events, intubation, and in-hospital mortality were also compared. Logistic regression analysis was performed to evaluate the association of CXR performance with door-to-needle time greater than or equal to 60 minutes. In the cohort of 615 patients, 243 had CXR done before IV thrombolytics. Patients with CXR before treatment had significantly higher admission neurologic deficit and initial respiratory rates. Patients with CXR done before treatment had longer mean door-to-needle times than those without pretreatment radiography (75.8 vs 58.3 minutes). The performance of CXR before IV thrombolytics prolongs door-to-needle time in acute ischemic stroke patients. CXR before treatment should be reserved for situations wherein acute cardiopulmonary conditions would otherwise preclude the administration of IV thrombolytics.
Banwell B. Pediatric multiple sclerosis. Neurology. 2016;87(8):822–826. doi:10.1212/WNL.0000000000003014.
This is the 2015 Sydney Carter Award Lecture in which Dr. Banwell summarizes the learning curve and milestones achieved in pediatric multiple sclerosis care and research to date.
Dr. Banwell notes that the available MS diagnostic criteria proposed by Poser in 1983 specifically excluded the diagnosis of MS in persons younger than ten years, and did not formally comment on MS in youth. Further complicating the diagnosis and care of pediatric patients with MS is …
We are pleased to announce that all AJNR readers are now able to earn 20 AMA PRA Category 1 Credits each year through for[CME]. Previously, AJNR readers were able to enjoy a 25% discount. However, due to our partnership with for[CME], you can now enjoy 20 CME Credits per year for free.
With for[CME] you will be able to enjoy the following benefits:
- Earn CME by searching for and reading AJNR articles
- 20 AMA PRA Category 1 Credits per year for free
- Access CME opportunities on the iOS and Android apps
- Search from millions of other peer-reviewed research abstracts
Click here to begin enjoying this benefit.
If you require assistance activating your account, then please reach out to for[CME] at firstname.lastname@example.org. We hope that you enjoy this new opportunity for American Journal of Neuroradiology readers.
Mossa-Basha M, de Havenon A, Becker KJ, et al. Added Value of Vessel Wall Magnetic Resonance Imaging in the Differentiation of Moyamoya Vasculopathies in a Non-Asian Cohort. Stroke. 2016;47(7):1782–1788. doi:10.1161/STROKEAHA.116.013320.
Moyamoya vasculopathy is divided into moyamoya disease (MMD) and moyamoya syndrome (MMS). This is a steno-occlusive process of the carotid termini, proximal middle cerebral artery, and anterior cerebral artery with development of compensatory collaterals. If patients have a well-recognized associated condition, then it is called moyamoya syndrome, whereas those patients with no known associated risk factors are said to have moyamoya disease. By definition, the pathognomic arteriographic findings are bilateral in moyamoya disease (although severity can vary between sides). Patients with unilateral findings have moyamoya syndrome, even if they have no other associated risk factors. MMS may arise secondary to many underlying disease processes, including sickle cell anemia, NF1, radiation therapy, congenital syndromes, intracranial atherosclerotic disease (A-MMS), and vasculitis (V-MMS). Making a correct and specific diagnosis will alter management, since MMD is treated by surgical revascularization, whereas the SAMMPRIS trial showed that aggressive medical management is the first-line therapy for a patient with high-grade (70%–99%) atherosclerotic stenosis. In this study, 10 atherosclerotic disease related MMS patients, 3 vasculitis disease related MMS patients, and 8 moyamoya disease patients with 38 affected carotid segments were evaluated with vessel wall MR. The most common vessel wall MRI findings for moyamoya disease were nonenhancing, nonremodeling lesions without T2 heterogeneity; for A-MMS eccentric, remodeling, and T2 heterogeneous lesions with mild/moderate and homogeneous / heterogeneous enhancement; and for V-MMS concentric lesions with homogeneous, moderate enhancement. There was an 11% inter-reader agreement for diagnosis on luminal imaging when compared with 82% for luminal imaging + vessel wall MRI. They conclude that vessel wall MRI improves diagnostic accuracy and diagnostic confidence in the differentiation of MMD from …
AJNR is proud to highlight our partnership with Publons during Peer Review Week 2016 as we showcase our commitment to honoring the efforts of our peer reviewers. These experts help ensure the publication of solid science that is relevant and robust before it gets communicated to the world. We encourage our reviewers to act upon this year’s theme of Recognizing Review and sign up for Publons now to effortlessly track, verify, and showcase every review they complete for AJNR and other Publons-affiliated journals. By registering, our reviewers will be eligible for Publons’ inaugural Sentinels of Science awards, paying homage to the most prolific heroes of peer review over the past year.
Follow the Twitter feed on this week’s activities at #PeerRevWk16 with @publons.…
Gondi V, Yock TI, Mehta MP. Proton therapy for paediatric CNS tumours — improving treatment-related outcomes. Nat Rev Neurol. 2016;12(6):334–345. doi:10.1038/nrneurol.2016.70.
In this review, the authors provide an introduction to the types of pediatric CNS tumors for which proton therapy can be considered, and discuss the evidence that proton therapy limits toxicities and improves quality of life for patients. As you no doubt remember from your residency, a proton has a defined maximum penetration depth, called the Bragg peak, at which the majority of its energy is released over a few millimeters. The Bragg peak is determined by the energy of a proton, and can be shortened to match the distal edge of the target by placement of customized tissue-equivalent material in the beam path. Before reaching the Bragg peak, a proton loses only a small amount of its energy, so delivers a lower ‘entrance’ dose than does conventional X‑ray therapy. Beyond the Bragg peak, a proton has no energy, so delivers no ‘exit’ dose. The improvement in dose distribution achieved with proton therapy can meaningfully affect the risk of long-term radiotherapy effects, such as secondary malignancy, cognitive toxicity, endocrinopathy, hearing loss and vasculopathic effects. Despite its higher up front costs, proton therapy has been shown to be more cost effective than X ray therapy owing to the dramatic reduction in the excess costs of managing long-term toxicities. Keep in mind that randomized trials of proton ther¬apy versus X ray therapy are unlikely due to the rarity of the diseases involved and the ethical issues surrounding the enrollment of children into trials in which one arm is asso¬ciated with a greater likelihood of toxicity. Uncertainty about the biological effects of proton therapy on certain healthy tissue and the relative inaccessibility of proton therapy, especially in developing nations, pose important …